ライフサイエンスコーパス: IVF

1 IVF being a medical procedure that aims at manipulating

2 IVF increases the risk of PTB and causes epigenetic chan

3 IVF placentae, however, displayed hypomethylation of imp

4 IVF procedure is divided into four stages: Superovulatio

5 IVF sensitivity, CS, and VA were not associated with hom

6 IVF sensitivity, CS, and VA were not associated with tot

7 IVF with PGD is a viable option for couples who wish to

8 IVFs of 3 mm or greater were associated with placenta pe

9 en 1980 and 1995 (non-IVF group) from all 12 IVF clinics in the Netherlands.

10 FINDINGS: We assessed 124,148 IVF cycles overall, which yielded 33,514 livebirths.

11 Among 137 women undergoing 180 IVF cycles, urinary BPA concentrations had a geometric m

12 From the 1880s, IVF began to be administered perioperatively to compensa

13 started IVF treatment between 1983 and 1995 (IVF group) and 5950 women starting other fertility treat

14 nt in the Netherlands between 1980 and 1995, IVF treatment compared with non-IVF treatment was not as

15 les (HR, 0.55 [95% CI, 0.39-0.77]) vs 1 to 2 IVF cycles and after poor response to the first IVF cycl

16 Couples (n = 218) underwent 195 IUI and 211 IVF cycles.

17 udy of 156,947 UK women who received 257,398 IVF ovarian stimulation cycles between 2003 and 2010 and

18 born after an IVF procedure and comparing 5 IVF procedures used in Sweden vs IVF without ICSI with f

19 rmula: see text] analyses and 339 women (512 IVF cycles) for the BC analysis enrolled in a prospectiv

20 We included 345 women (522 IVF cycles) for the [Formula: see text], [Formula: see t

21 +/- 4.2 years at enrollment contributed 774 IVF cycles.

22 apy was delivered in 23 patients (29%) of 78 IVF patients with an implantable cardioverter-defibrilla

23 the hysteroscopy group had a livebirth after IVF compared with 102 (29%) women in the control group (

24 imited information on neurodevelopment after IVF exists, especially after the first year of life.

25 f mature eggs reached the 2-cell stage after IVF in animals receiving a 3 and 5 days ZDD, respectivel

26 which includes data on more than 95% of all IVF cycles performed in the United States.

27 ase in long-term risk of breast cancer among IVF-treated women.

28 Breast cancer risk among IVF-treated women was also not significantly different f

29 rine surgery (aOR 3.40, 95%CI 1.30-8.91), an IVF pregnancy (aOR 32.13, 95%CI 2.03-509.23) and placent

30 conceived offspring with those born after an IVF procedure and comparing 5 IVF procedures used in Swe

31 sociations were observed between DDT/DDE and IVF outcomes or between HCB and chemical pregnancy or sp

32 glaucoma and subjects in whom better-eye and IVF MD differed by >/= 2 dB.

33 ompare the relative impact of better-eye and IVF MD on driving habits, mobility, self-reported vision

34 The median difference between better-eye and IVF MD was 0.41 dB (interquartile range [IQR], -0.21 to

35 Differences between better-eye and IVF MD were calculated for SEE and clinic-based subjects

36 field testing was performed in each eye, and IVF MD was calculated.

37 ocyst tcRNA isolated from individual IVO and IVF produced embryos for miR-18a, -21, and -24.

38 ing early embryonic development from IVO and IVF sources are required to further examine and evaluate

39 relation between serum pesticide levels and IVF outcomes.

40 d mortality rates in the CLEAR III study and IVF represents a safe and effective strategy to hasten c

41 n age of 59.1 years (range, 19-86 years) and IVF mean deviation (MD) of -4.84 dB (range, -27.56 to 2.

42 ome assessment (n = 174) was 71.1 years, and IVF sensitivity ranged from 5.6 to 33.4 dB (mean = 27.2

43 hereas 31 (44.9%) cases not treated with any IVF survived (P = .583).

44 0.9% NaCl is the most appropriate IVF for the majority of hospitalized children.

45 uals at risk, because except for arrhythmia, IVF does not manifest with identifiable clinical abnorma

46 sociated with an elevated odds of failing at IVF prior to live birth ([Formula: see text], 95% CI: 0.

47 95% confidence intervals (CI) of failing at IVF.

48 specific uterine cavity abnormalities before IVF is warranted.

49 Outpatient hysteroscopy before IVF in women with a normal ultrasound of the uterine cav

50 l and placental tissues postpartum from both IVF and naturally conceived children, to investigate the

51 graphic and clinical factors related to both IVF exposure and survival, cases were compared using pro

52 s, had their chance of fathering children by IVF or ICSI reduced by nearly two-thirds.

53 nfants born, 30,959 (1.2%) were conceived by IVF and were followed up for a mean 10 (SD, 6) years.

54 %) with mental retardation were conceived by IVF.

55 cided with reduced incidence of pregnancy by IVF or ICSI, identifying SPTRX3 as a candidate biomarker

56 on analysis detected methylated changes in C-IVF, but not in Natur-IVF, at genes whose methylation co

57 ur-IVF embryos were of higher quality than C-IVF in terms of cell number and hatching ability.

58 sts were produced in vitro either without (C-IVF) or in the presence of natural reproductive fluids (

59 al adoption-at-birth study), and the Cardiff IVF (In Vitro Fertilization) Study (an adoption-at-conce

60 r fluid tonicity with admixtures of clinical IVFs affects sRBC biomechanical properties by leveraging

61 Compared with spontaneous conception, IVF treatment overall was not associated with autistic d

62 cles; reproductive outcomes for conventional IVF and ICSI cycles during 2008-2012, stratified by the

63 RR, 0.93; 95% CI, 0.91-0.95) vs conventional IVF.

64 ltiple birth rate compared with conventional IVF (30.9% vs 34.2%; adjusted relative risk [RR], 0.87;

65 Compared with conventional IVF, ICSI use was not associated with improved postferti

66 the transfer of three or more embryos during IVF (P<0.001) and a 33% decrease in the proportion of tr

67 the transfer of three or more embryos during IVF.

68 s-in the context of agonist treatment during IVF-these receptors act as 'suicidal' segregation distor

69 pollution during OS was strongest for early IVF failures.

70 nts was associated with higher odds of early IVF failure.

71 The primary limiting factor for effective IVF treatment is successful embryo implantation.

72 (ES cells) from in vitro fertilized embryos (IVF ES cells) represent the 'gold standard', they are al

73 in vitro fertilization embryo-derived ESCs (IVF-ESCs).

74 entration, and the number of previous failed IVF cycles.

75 s and development of in vitro fertilisation (IVF) and how it was influenced by, and influenced, basic

76 The success rate of in-vitro fertilisation (IVF) remains low and many women undergo multiple treatme

77 echnologies, such as in-vitro fertilisation (IVF) with intracytoplasmic sperm injection (ICSI), can b

78 Following in vitro fertilisation (IVF), only about half of normally fertilised human embry

79 During in vitro fertilisation (IVF), pharmacological activation of the murine X chromos

80 nancy outcomes after in-vitro fertilisation (IVF).

81 ing odds ratios with in vitro fertilization (IVF) (165 birth defects, 7.2%) were 1.26 (95% CI, 1.07 t

82 as oocyte donors for in vitro fertilization (IVF) and as recipients for embryo transfer.

83 RG mice by combining in vitro fertilization (IVF) and CRISPR/Cas9 technology.

84 enetic activation or in vitro fertilization (IVF) and tracked their development.

85 ouples who underwent in vitro fertilization (IVF) and/or intrauterine insemination (IUI) cycles in a

86 embryos generated by in vitro fertilization (IVF) but not SCNT.

87 ryos created through in vitro fertilization (IVF) do not implant.

88 genomic screening in in vitro fertilization (IVF) enables accurate and cost-effective selection of no

89 nital anomalies, and in vitro fertilization (IVF) failure in humans.

90 in women undergoing in vitro fertilization (IVF) from 1994 to 2003.

91 h rates, and data on in vitro fertilization (IVF) from 1997 through 2011 were used to estimate the an

92 oocyte donation for in vitro fertilization (IVF) has increased in the United States, but little info

93 oncepti generated by in vitro fertilization (IVF) in two different genetic backgrounds.

94 in vitro fertilization (IVF) is one of the most highly pursued assisted reproduc

95 In vitro fertilization (IVF) is the most common assisted reproductive technology

96 In vitro fertilization (IVF) is the most widely used technique in assisted repro

97 ve birth with repeat in vitro fertilization (IVF) is unclear, yet treatment is commonly limited to 3

98 rian stimulation and in vitro fertilization (IVF) methods established for Chinese cynomolgus macaques

99 ) couples treated by in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI).

100 ate metabolites with in vitro fertilization (IVF) outcomes, accounting for multiple IVF cycles per wo

101 black carbon (BC) on in vitro fertilization (IVF) outcomes.

102 diagnosis (PGD) and in vitro fertilization (IVF) performed for the prevention of genetic prion disea

103 estigates changes in in vitro fertilization (IVF) rates among health plan enrollees between 2012 and

104 matozoa were used in in vitro fertilization (IVF) studies, and when followed by embryo transfer, >/=

105 rus partially rescue in vitro fertilization (IVF) that failed with epididymal spermatozoa alone.

106 ites and outcomes of in vitro fertilization (IVF) treatment among couples recruited from an academic

107 st cancer risk after in vitro fertilization (IVF) treatment were inconclusive due to limited follow-u

108 ants were born after in vitro fertilization (IVF) treatments.

109 oocyte retrieval for in vitro fertilization (IVF) with a positive home pregnancy test, abdominal dist

110 ryogenesis following in vitro fertilization (IVF)(1-3), its rate in naturally conceived human embryos

111 Before 8 h of in vitro fertilization (IVF), a mechanism exists that inhibits the association o

112 hormone stimulation, in vitro fertilization (IVF), embryo culture and embryo transfer.

113 fertility treatment (in vitro fertilization (IVF), non-IVF/study site, and non-IVF/outside clinic).

114 and women undergoing in vitro fertilization (IVF), we consider it an ovarian toxicant.

115 set of zygotes from in vitro fertilization (IVF), we find that success in progression to the blastoc

116 (ICSI) and standard in vitro fertilization (IVF), we found that Ca(2+) influx was not required to in

117 n of sperm cells for in vitro fertilization (IVF).

118 who were undergoing in vitro fertilization (IVF).

119 it over conventional in vitro fertilization (IVF).

120 ong women undergoing in vitro fertilization (IVF).

121 ryos created through in vitro fertilization (IVF).

122 patients undergoing in vitro fertilization (IVF).

123 allowed during human in vitro fertilization (IVF).

124 hose conceived using in vitro fertilization (IVF).

125 in women undergoing in vitro fertilization (IVF).

126 patients undergoing in vitro fertilization (IVF).

127 who were undergoing in vitro fertilization (IVF); miRNA levels were determined from a miRNA data set

128 etic diagnosis (PGD) of in vitro fertilized (IVF) embryos do not detect de novo single-nucleotide and

129 Idiopathic ventricular fibrillation (IVF) is a rare cause of sudden cardiac arrest.

130 ly with idiopathic ventricular fibrillation (IVF) manifesting in childhood and adolescence.

131 treatment by intraventricular fibrinolysis (IVF) was recently linked to reduced mortality rates in t

132 egression analysis, the MD of the full-field IVF showed positive associations with near activities (b

133 Binocular integrated visual fields (IVFs) using a best location method were constructed for

134 cycles and after poor response to the first IVF cycle (HR, 0.77 [95% CI, 0.61-0.96] for <4 vs >/=4 c

135 Intravenous fluid (IVF) is a frequently recommended intervention in Ebola v

136 vance to modern practice.Intravenous fluids (IVF) first gained therapeutic importance in the treatmen

137 Clinical intravenous fluids (IVFs) of various tonicities are often used during treatm

138 rinciples of prescribing intravenous fluids (IVFs) to the acutely ill child and of adjusting sodium c

139 Following IVF embryos were cultured to the blastocyst stage in vit

140 d with fertilization or live birth following IVF.

141 prenatal development and at birth, following IVF treatment, is well understood.

142 oscopy improves the livebirth rate following IVF treatment in women with recurrent failure of implant

143 from males with high DFI (62.7 +/- 7.2% for IVF and 73.3 +/- 8.1% for ICSI) failed to litter after e

144 s from males with low DFI (20.4 +/- 7.9% for IVF and 28.1 +/- 10.7 for ICSI).

145 ty of Michigan) began providing coverage for IVF in 2015.

146 Gene discovery for IVF is important as it enables the identification of ind

147 e year when clinical practice guidelines for IVF were developed with an aim toward reducing the incid

148 otentially improve greatly the prospects for IVF treatment.

149 Information on ovarian stimulation for IVF, other fertility treatments, and potential confounde

150 Of the 1,395,634 fresh IVF cycles from 1996 through 2012, 908,767 (65.1%) used

151 Among fresh IVF cycles in the United States, ICSI use increased from

152 trospective cohort study using data on fresh IVF and ICSI cycles reported to the US National Assisted

153 genetic aberrations that probably arose from IVF-related CIN.

154 nt-ESC counterparts than those derived from IVF-ESCs.

155 Inferior hemifield IVF impacted vision-specific role difficulties and gener

156 .001) while the MD of the inferior hemifield IVF was associated with general vision (beta = 0.04; R2

157 tionnaire and superior or inferior hemifield IVF was determined using multivariable linear regression

158 showed that the MD of the superior hemifield IVF was associated only with near activities (beta = 0.0

159 Superior hemifield IVF was strongly associated with difficulty with near ac

160 Her IVF cycle included the usual cocktail for gonadotropin s

161 It also considers how IVF has contributed, and continues to contribute, to our

162 tential to become a common practice in human IVF procedures, as well as to significantly simplify and

163 ng method, genetically matched sets of human IVF ES cells, iPS cells and nuclear transfer ES cells (N

164 Our findings affirm that human IVF treatment has no detrimental effect on the chromosom

165 historic approach of administering hypotonic IVFs results in a high incidence of hospital-acquired hy

166 l reconstruction versus sperm retrieval/ICSI/IVF are neither randomized nor homogenous.

167 trate that the model can be used to identify IVF patients who produce an extreme number of aneuploid

168 Mortality rate was 9% in IVF patients (8/85).

169 ecurrence rate of ventricular arrhythmias in IVF patients is high.

170 Each 5-dB decrement in IVF sensitivity was associated with 16.3 fewer active mi

171 h follow-up and reassessment of diagnosis in IVF patients.

172 ndation for a future RNA-based diagnostic in IVF.

173 f SNPs in p63 and p73 genes were enriched in IVF patients.

174 ity is a major cause of pregnancy failure in IVF programs.

175 uction of time-lapse imaging improvements in IVF success rates have failed to materialize, therefore

176 ough numerous advancements have been made in IVF procedures, little attention has been given to modif

177 oth oocyte ranking and embryo preferences in IVF applications.

178 ral DNA imbalances occur at similar rates in IVF and naturally conceived live-born neonates.

179 Breast cancer risk in IVF-treated women was not significantly different from t

180 Embryo selection for transfer in IVF cycles relies on the morphological evaluation by emb

181 Secondary endpoints included IVF- and LD-related safety, such as bleeding or infectio

182 soldiers from the Korean War receiving large IVF infusions and surviving, dictated the surgical pract

183 g, dictated the surgical practice of liberal IVF administration until very recently.Newer work in flu

184 In time-of-day analyses, lower IVF sensitivity was associated with fewer steps over the

185 Unlike better-eye MD, IVF measurements require extra software/calculation.

186 ntly lower for those who underwent 7 or more IVF cycles (HR, 0.55 [95% CI, 0.39-0.77]) vs 1 to 2 IVF

187 e, accounting for correlation among multiple IVF cycles in the same woman using generalized estimatin

188 tion (IVF) outcomes, accounting for multiple IVF cycles per woman.

189 s with IVF outcomes, accounting for multiple IVF cycles per woman.

190 Natur-IVF embryos were of higher quality than C-IVF in terms o

191 esence of natural reproductive fluids (Natur-IVF).

192 by culture, with fewer aberrations in Natur-IVF embryos.

193 ethylated changes in C-IVF, but not in Natur-IVF, at genes whose methylation could be critical, such

194 d DNA methylation analyses showed that Natur-IVF embryos have expression and methylation patterns clo

195 tility treatments between 1980 and 1995 (non-IVF group) from all 12 IVF clinics in the Netherlands.

196 ilization (IVF), non-IVF/study site, and non-IVF/outside clinic).

197 treatment (in vitro fertilization (IVF), non-IVF/study site, and non-IVF/outside clinic).

198 oup (0.92 [95% CI, 0.73-1.15]) or in the non-IVF group (1.03 [95% CI, 0.82-1.29]).

199 ardized incidence ratios [SIRs]) and the non-IVF group (hazard ratios [HRs]).

200 CI, 0.93-1.09]) and from the risk in the non-IVF group (HR, 1.01 [95% CI, 0.86-1.19]).

201 3.0% for the IVF group and 2.9% for the non-IVF group (P = .85).

202 for the IVF group and 55.3 years for the non-IVF group.

203 ths that were attributable to IVF and to non-IVF fertility treatments, after adjustment for maternal

204 80 and 1995, IVF treatment compared with non-IVF treatment was not associated with increased risk of

205 tricles) or a combined treatment approach of IVF and-upon clot clearance of third and fourth ventricl

206 ompared to IVF alone, a combined approach of IVF plus LD treatment is feasible and safe and significa

207 endency for a combined treatment approach of IVF plus lumbar drains (LDs).

208 ain outcome measures were the association of IVF sensitivity with fall rates per year or step, strati

209 hasized the importance of the composition of IVF and laid the foundations for the balanced solutions

210 e month before starting a treatment cycle of IVF (with or without intracytoplasmic sperm injection).

211 Successful development of IVF and CCR5 editing protocols in MCM embryos lays a fou

212 cutive patients with an initial diagnosis of IVF were analyzed (age at index event 40.4 years, 60% ma

213 Further, we evaluated the effects of IVF culture on the expression of specific miRNA at the b

214 The evolution of IVF has raised concerns of increased cancer risks, inclu

215 After 10 h of IVF the inhibition of G9a activity depends on yet unknow

216 sms of transfer take place between 8-10 h of IVF, and the novel protein failed to inhibit G9a activit

217 port the efficacy of extending the number of IVF cycles beyond 3 or 4.

218 age at baseline, 32.8 years; mean number of IVF cycles, 3.6), 839 cases of invasive breast cancer an

219 ta are available on the long-term outcome of IVF patients.

220 NT ES cells corresponded closely to those of IVF ES cells, whereas iPS cells differed and retained re

221 rospective clinical study addressing optimal IVF management during VOE in SCD.

222 ion induction, intrauterine insemination, or IVF did not differ significantly between the groups.

223 ion induction, intrauterine insemination, or IVF.

224 Live-birth rate per IVF cycle and the cumulative live-birth rates across all

225 5) who provided one or two urine samples per IVF cycle.

226 0.9% NaCl is the preferred IVF for the vast majority of hospitalized children.

227 hylation in placentas from term IVF, preterm IVF, term control (unassisted conception) and preterm co

228 For specific procedures, IVF with ICSI for paternal infertility was associated wi

229 lation in fetal brain or liver samples, rare IVF concepti displayed very low methylation and abnormal

230 standard treatment (control group receiving IVF consisting of 1mg of recombinant human tissue plasmi

231 n overall 97 patients, 45 patients receiving IVF plus LD versus 42 with IVF only.

232 majority of hospitalized children requiring IVFs are at risk for developing hyponatremia from numero

233 We observed decreased success for several IVF outcomes across increasing quartiles of both summed

234 The cohort included 19,158 women who started IVF treatment between 1983 and 1995 (IVF group) and 5950

235 d efficacy and safety of a combined strategy-IVF plus LD versus IVF alone-on shunt dependency in pati

236 -wide DNA methylation in placentas from term IVF, preterm IVF, term control (unassisted conception) a

237 Does ICSI have consequences that IVF does not?

238 in sFLT1 observed in this study suggest that IVF procedures could increase the risk for preeclampsia.

239 The IVF MD rarely differs from better-eye MD, and similar as

240 The IVF was further stratified by VF location (superior vs i

241 relationship significantly varied across the IVF cycle such that the association with higher exposure

242 IVM restored histone H3K4me3 and doubled the IVF success rate from 17% to 43% in oocytes from zinc de

243 of breast cancer at age 55 were 3.0% for the IVF group and 2.9% for the non-IVF group (P = .85).

244 e at end of follow-up was 53.8 years for the IVF group and 55.3 years for the non-IVF group.

245 ghrelin, number of oocytes retrieved in the IVF cycle, and pregnancy rate were determined.

246 18 +/- 0.87, respectively; P = 0.039) in the IVF cycle.

247 er time since treatment (>/=20 years) in the IVF group (0.92 [95% CI, 0.73-1.15]) or in the non-IVF g

248 Breast cancer risk in the IVF group was compared with risks in the general populat

249 Overall, 42% (n = 75) of the IVF cycles resulted in implantation failure.

250 ior compared with the inferior region of the IVF ranged from 2.1 (95% confidence interval, 2.1-2.4) t

251 , [Formula: see text], and BC throughout the IVF cycle was associated with an elevated odds of failin

252 the sensitivity values (in decibels) of the IVFs to determine common defect patterns in an automated

253 Furthermore, embryos created through IVF are currently evaluated for developmental potential

254 of fertilized embryos were produced through IVF, and a high rate of Fah gene targeting was achieved

255 plet and higher-order births attributable to IVF (P<0.001).

256 of multiple births that were attributable to IVF and to non-IVF fertility treatments, after adjustmen

257 in patients with severe IVH, as compared to IVF alone, a combined approach of IVF plus LD treatment

258 -tangential pronuclear alignment compared to IVF zygotes.

259 us on perioperative fluid therapy has led to IVF administration being guided by physiological princip

260 Five novel tripeptides, IVF, LLF, LNF, LSW and LEF, with predicted IC50 values l

261 Among women in the United Kingdom undergoing IVF, the cumulative prognosis-adjusted live-birth rate a

262 Vaginal samples from 120 patients undergoing IVF were sequenced using the V4 region of the 16S riboso

263 reproductive outcome in patients undergoing IVF.

264 Eligible women were undergoing IVF (fresh-embryo or frozen-embryo transfer), with no re

265 spective cohort study among women undergoing IVF at the Massachusetts General Hospital Fertility Cent

266 h failed implantation among women undergoing IVF.

267 than no intervention among women undergoing IVF.

268 We identified a mutation in CALM1 underlying IVF manifesting in childhood and adolescence.

269 vity and history of two to four unsuccessful IVF cycles.

270 uterine cavity and a history of unsuccessful IVF treatment cycles does not improve the livebirth rate

271 treatment of women who fail to conceive upon IVF and suggests new avenues for developing intervention

272 Using IVF to investigate human reproduction and pregnancy outc

273 ty of a combined strategy-IVF plus LD versus IVF alone-on shunt dependency in patients with ICH and s

274 obtained to calculate average integrated VF (IVF) sensitivity.

275 age VF sensitivity within the integrated VF (IVF).

276 were transformed to binocular integrated VF (IVF).

277 ment and between in vivo (IVO) and in vitro (IVF) produced embryos.

278 yo development after fertilization in vitro (IVF), but the available embryo culture medium in the cur

279 comparing 5 IVF procedures used in Sweden vs IVF without ICSI with fresh embryo transfer, the most co

280 The exposure of interest was IVF, categorized according to whether intracytoplasmic s

281 g, and there is no consensus regarding which IVFs to use during VOE.

282 atients receiving IVF plus LD versus 42 with IVF only.

283 reased risk of birth defects associated with IVF was no longer significant after adjustment for paren

284 he increase in absolute risk associated with IVF was small.

285 Compared with IVF without ICSI with fresh embryo transfer, there were

286 isorder and mental retardation compared with IVF without ICSI.

287 fth of the patients initially diagnosed with IVF reveal a specific diagnosis during long-term follow-

288 osted tree model, IVFBT, by training it with IVF outcomes data from 1,676 first cycles (C1s) from 200

289 the association of the PFR metabolites with IVF outcomes, accounting for multiple IVF cycles per wom

290 F (27.3%) compared to those not treated with IVF (26.9%) during their entire ETU admission (P = .893)

291 ce in 28-day survival for cases treated with IVF (27.3%) compared to those not treated with IVF (26.9

292 urvival among patients with EVD treated with IVF as compared to those not treated with IVF.

293 for analysis, 354 (83.5%) were treated with IVF at some point during their ETU admission.

294 l between cases treated and not treated with IVF during their first 24 and 48 hours of care.

295 Overall, 146 (41.3%) cases treated with IVF survived, whereas 31 (44.9%) cases not treated with

296 l between cases treated and not treated with IVF.

297 th IVF as compared to those not treated with IVF.

298 nces in away vs home steps did not vary with IVF sensitivity (P = .22).

299 w altering extracellular fluid tonicity with IVFs affects sRBC biomechanics in the microcirculation,

300 Worse IVF sensitivity was not associated with a higher rate of